{"schema_version":"secwatch.filing_event.v1","accession":"0001396814-23-000003","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2023-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.745712+00:00","generated_at":"2026-06-20T19:29:08.416873+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pacira BioSciences reports preliminary 2022 revenue of $666.8M, up 23.1% YoY","bullets":["EXPAREL net sales $536.9M in 2022 vs $506.5M in 2021; Q4 2022 sales $138.0M, roughly flat vs prior Q4.","ZILRETTA net sales $105.5M in 2022 vs $12.7M in 2021 (acquired Nov 2021); Q4 2022 sales $28.0M.","Adjusted EPS expected at least $2.50 for 2022, marking ninth consecutive year of positive adjusted earnings.","Prepaid $50M on Term Loan B in Dec 2022; plans another significant prepayment in 2023.","Management cites strong balance sheet, durable cash flows, and outperformance vs surgical market."],"urls":{"canonical":"https://secwatch.observer/filing/0001396814-23-000003","json":"https://secwatch.observer/filing/0001396814-23-000003.json","markdown":"https://secwatch.observer/filing/0001396814-23-000003.md","text":"https://secwatch.observer/filing/0001396814-23-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000003/0001396814-23-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000003/pcrx-20230105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T19:29:08.416873+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c2d9b4083d7a68a778ef89d4351977c3ff0a9426","claim":"Pacira BioSciences, Inc. reported 2022 results: EPS adjusted earnings per share of at least $2.50.","evidence_excerpt":"Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $666.8 million for 2022, compared with $541.5 million for 2021, representing an increase of 23.1 percent.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000003/0001396814-23-000003-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2022"},{"label":"EPS","value":"adjusted earnings per share of at least $2.50"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"c2d9b4083d7a68a778ef89d4351977c3ff0a9426","claim":"Pacira BioSciences, Inc. reported 2022 results: EPS adjusted earnings per share of at least $2.50.","evidence_excerpt":"We ended the year with a strong balance sheet and expect to report adjusted earnings per share of at least $2.50 for 2022, marking our ninth consecutive year of positive adjusted earnings.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000003/0001396814-23-000003-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2022"},{"label":"EPS","value":"adjusted earnings per share of at least $2.50"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}